Asset Details
Do you wish to reserve the book?
The health and economic burden of rare endocrine disease: Often ignored, always important
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The health and economic burden of rare endocrine disease: Often ignored, always important
Do you wish to request the book?
The health and economic burden of rare endocrine disease: Often ignored, always important
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The health and economic burden of rare endocrine disease: Often ignored, always important
2024
Overview
Rare endocrine diseases (RED) often pose chronic and life-threatening challenges, yet their economic costs and societal impact remains have not been precisely quantified.
We obtained patient data from the 2018 Nationwide Inpatient Sample (NIS) and the Nationwide Readmissions Database (NRD), identifying RED patients through International Classification of Diseases, 10th revision codes. The difference of economic burden between RED patients and the control group, including hospital length of stay, hospitalisation costs, and readmission rates, was assessed using chi-square tests.
We extracted 638 083 (2.98%) RED-related records from the NIS database. Compared to patients with common conditions, RED patients showed an exceedingly high burden of disease, including significantly extended hospital stays (P < 0.05), elevated total charges (P < 0.05), and heightened mortality rates (P < 0.05). They also had a substantially increased 30-day all-cause readmission rate based on the NRD database (P < 0.05). Although the different subgroups of RED patients had varying patterns of health care utilisation and economic burdens, they all surpassed those of patients with common conditions.
There is a need for novel strategies aimed at mitigating the substantial RED-related burdens borne by individuals, families, and society in general, as well as funding for research and clinical trials.
Publisher
International Society of Global Health
Subject
/ Adult
/ Aged
/ Endocrine System Diseases - economics
/ Endocrine System Diseases - epidemiology
/ Female
/ Health Care Costs - statistics & numerical data
/ Hospitalization - statistics & numerical data
/ Humans
/ Length of Stay - statistics & numerical data
/ Male
/ Patient Readmission - economics
